Plain-English translation of NCT05044962 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
This study doesn't follow the usual testing phases — it may be an observational study or a different type of research.
This trial is testing cabotegravir and rilpivirine, two medications given as injections instead of daily pills, to treat HIV in young women ages 15–24. The study also looks at how this injectable treatment works when used together with different birth control options. Researchers want to see if this approach helps people stick with their HIV treatment and manage both their health conditions more easily.
Many young women with HIV struggle to take daily HIV pills, which can make their treatment less effective. At the same time, preventing unintended pregnancy is also critical for their health. This study explores whether offering a long-acting injectable treatment might help young women manage both HIV and contraception more successfully.
You likely qualify if…
You likely don't qualify if…
Participants will receive either the new injectable HIV medication paired with their choice of birth control method, or continue taking their current daily HIV pills. The study involves regular blood draws every 4–12 weeks over 48 weeks (about 1 year) to check how well the medication is working. Some participants will also take part in interviews or focus groups to share their experiences and help healthcare providers understand how to offer this treatment to more young women.
AI-generated summary from trial data · Jun 17, 2026 · Not medical advice
Kenya